Compare ARTNA & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARTNA | CNTX |
|---|---|---|
| Founded | 1905 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.1M | 283.9M |
| IPO Year | N/A | 2021 |
| Metric | ARTNA | CNTX |
|---|---|---|
| Price | $31.87 | $2.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 64.5K | ★ 800.7K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | $15.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.50 | $0.49 |
| 52 Week High | $36.19 | $3.62 |
| Indicator | ARTNA | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.03 | 46.80 |
| Support Level | $31.35 | $2.07 |
| Resistance Level | $32.34 | $2.58 |
| Average True Range (ATR) | 0.81 | 0.26 |
| MACD | 0.07 | -0.05 |
| Stochastic Oscillator | 62.05 | 14.20 |
Artesian Resources Corp operates as a holding company with a focus on water distribution and wastewater services. Its regulated utility segment includes subsidiaries providing water and wastewater services in Delaware, Maryland, and Pennsylvania. Water distribution spans residential, commercial, industrial, and municipal sectors, while wastewater services are offered in Sussex County, Delaware. The company also engages in non-utility businesses, offering service line protection plans, engineering services, and contract operations for water and wastewater systems. The regulated utility segment constitutes the portion of the company's operations, subject to regulations by Delaware, Maryland, and Pennsylvania.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.